Lanreotide vs Prostatilen
Overview
Lanreotide and Prostatilen are both hormonal peptides, but they differ in mechanism, dosing, and regulatory status.
This page compares Lanreotide and Prostatilen across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Lanreotide | Prostatilen | |
|---|---|---|
| Category | Hormonal | Hormonal |
| Regulatory status (US) | FDA approved | Research use only |
| Typical dosage | 60-120 mg | 10 mg |
| Frequency | every 4 weeks | daily for cycles |
| Reported benefits | suppression of excess growth hormone and IGF-1 in acromegaly, improved progression-free survival in GEP-NETs, reduction of carcinoid syndrome symptoms, inhibition of multiple GI and pancreatic hormones | Prostate health, reproductive function, hormone balance |
| Reported side effects | diarrhea, cholelithiasis, abdominal pain, hyperglycemia, bradycardia, injection site reactions, nausea, hypertension, headache, thyroid function decreases | Well-tolerated |
Key differences
Primary use. Lanreotide is categorised under Hormonal, while Prostatilen falls under Hormonal. Because they target a similar goal, they are common alternatives to weigh against each other.
Regulatory status. Lanreotide: FDA-approved. Prostatilen: not FDA-approved; treated as a research compound.
Dosing. Lanreotide is typically dosed at 60-120 mg (every 4 weeks). Prostatilen is typically dosed at 10 mg (daily for cycles).
Can you stack them?
Some protocols combine peptides, but stacking Lanreotide and Prostatilen has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Lanreotide and Prostatilen?
- Lanreotide and Prostatilen are both hormonal peptides, but they differ in mechanism, dosing, and regulatory status. Lanreotide is FDA-approved for one or more indications, whereas Prostatilen is not FDA-approved; generally classified as a research compound.
- What is Lanreotide used for?
- FDA-approved long-acting somatostatin analog for acromegaly, GEP-NETs, and carcinoid syndrome.
- What is Prostatilen used for?
- Prostate and male hormone support.
- Can you take Lanreotide and Prostatilen together?
- Some users combine peptides within a single protocol, but stacking Lanreotide and Prostatilen has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Lanreotide or Prostatilen FDA-approved?
- Lanreotide is FDA-approved for one or more indications. Prostatilen is not FDA-approved; generally classified as a research compound.
Read the full articles
- Lanreotide — full monograph: mechanism, research, dosing & references
- Prostatilen — full monograph: mechanism, research, dosing & references